Brokerages Set Bath & Body Works, Inc. (NYSE:BBWI) Target Price at $21.93

Bath & Body Works, Inc. (NYSE:BBWI) has been assigned a consensus rating of “Hold” from the eighteen analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, fourteen have given a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $21.9286.

BBWI has been the topic of several research reports. Jefferies Financial Group raised their price target on Bath & Body Works from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Tuesday, July 28th. TD Cowen increased their target price on shares of Bath & Body Works from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Wells Fargo & Company raised their target price on shares of Bath & Body Works from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, June 23rd. Telsey Advisory Group reduced their price target on shares of Bath & Body Works from $25.00 to $22.00 and set a “market perform” rating for the company in a report on Thursday, May 28th. Finally, UBS Group lowered their price target on shares of Bath & Body Works from $22.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, May 20th.

Bath & Body Works Stock Performance

Shares of NYSE BBWI opened at $18.75 on Tuesday. Bath & Body Works has a 52-week low of $14.27 and a 52-week high of $32.32. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of 5.27, a PEG ratio of 1.92 and a beta of 1.38. The stock has a 50 day moving average price of $20.38 and a 200 day moving average price of $20.14.

Bath & Body Works (NYSE:BBWI) last released its quarterly earnings data on Wednesday, May 27th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.29 by $0.03. The company had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.36 billion. Bath & Body Works had a negative return on equity of 45.34% and a net margin of 10.03%.Bath & Body Works’s quarterly revenue was down 3.2% on a year-over-year basis. During the same period last year, the business posted $0.49 EPS. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. Analysts forecast that Bath & Body Works will post 2.63 earnings per share for the current year.

Bath & Body Works Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 4th. Investors of record on Friday, August 21st will be paid a $0.20 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 4.3%. Bath & Body Works’s payout ratio is 22.47%.

Institutional Trading of Bath & Body Works

Several hedge funds and other institutional investors have recently bought and sold shares of BBWI. Royal Bank of Canada raised its position in shares of Bath & Body Works by 92.8% in the 1st quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock worth $1,815,000 after acquiring an additional 28,815 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Bath & Body Works by 15.7% during the first quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock valued at $19,586,000 after purchasing an additional 87,529 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Bath & Body Works by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock valued at $17,063,000 after purchasing an additional 36,684 shares in the last quarter. Intech Investment Management LLC purchased a new position in Bath & Body Works in the first quarter valued at about $1,155,000. Finally, Geneos Wealth Management Inc. grew its stake in Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock valued at $35,000 after purchasing an additional 801 shares during the last quarter. Institutional investors own 95.14% of the company’s stock.

About Bath & Body Works

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.